← Back to Search

Norepinephrine-Dopamine Reuptake Inhibitor

Centanafadine for Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 1
Waitlist Available
Research Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing a new treatment for children aged 4 to 12 years who have ADHD. The goal is to see how effective and safe the treatment is over time.

Eligible Conditions
  • Attention-Deficit/Hyperactivity Disorder (ADHD)

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2019 Phase 2 trial • 13 Patients • NCT04081363
14%
Vessel Puncture Site Bruise
100%
80%
60%
40%
20%
0%
Study treatment Arm
Swallowed Capsules Cohort
Sprinkled Onto Applesauce Cohort

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open-label centanafadineExperimental Treatment1 Intervention
There will be multiple cohorts dosed with open-label centanafadine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Centanafadine
2019
Completed Phase 2
~300

Find a Location

Who is running the clinical trial?

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
264 Previous Clinical Trials
170,030 Total Patients Enrolled
~11 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top